Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $8.13 Consensus Target Price from Analysts

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have been assigned a consensus rating of “Hold” from the five research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $7.30.

Several equities analysts recently issued reports on ESPR shares. The Goldman Sachs Group initiated coverage on shares of Esperion Therapeutics in a report on Wednesday. They set a “neutral” rating and a $4.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a report on Friday, December 13th. Cantor Fitzgerald started coverage on Esperion Therapeutics in a research report on Tuesday. They issued an “overweight” rating and a $8.00 price target for the company. StockNews.com downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research note on Thursday, December 12th.

Esperion Therapeutics Stock Performance

NASDAQ ESPR opened at $2.19 on Wednesday. Esperion Therapeutics has a one year low of $1.58 and a one year high of $3.94. The company has a market capitalization of $431.51 million, a price-to-earnings ratio of -3.42 and a beta of 1.01. The company’s 50-day simple moving average is $2.42 and its two-hundred day simple moving average is $2.22.

Institutional Investors Weigh In On Esperion Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wasatch Advisors LP raised its holdings in shares of Esperion Therapeutics by 38.4% in the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after buying an additional 6,483,070 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Esperion Therapeutics by 4.1% in the 3rd quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after acquiring an additional 171,609 shares during the period. Marshall Wace LLP raised its stake in Esperion Therapeutics by 94.2% in the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock worth $9,554,000 after acquiring an additional 2,087,635 shares during the last quarter. State Street Corp lifted its position in Esperion Therapeutics by 2.7% during the 3rd quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock worth $6,360,000 after acquiring an additional 99,802 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in Esperion Therapeutics by 71.0% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock valued at $1,174,000 after purchasing an additional 295,378 shares during the last quarter. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.